A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)

Trial Profile

A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Aug 2018

At a glance

  • Drugs Hepatitis B vaccine recombinant (Primary)
  • Indications Hepatitis B
  • Focus Registrational; Therapeutic Use
  • Acronyms CONSTANT
  • Sponsors VBI Vaccines
  • Most Recent Events

    • 26 Jul 2018 According to a VBI Vaccines media release, topline data from this trial is expected in the second half of 2019.
    • 01 May 2018 According to a VBI Vaccines media release, topline data are expected mid-year 2019.
    • 19 Dec 2017 According to a VBI Vaccines media release, based on the results of this trail and other phase III trial (281672), company expects to submit marketing authorization applications to U.S., European, and Canadian regulatory authorities in 2019. Also, Dr. Nathan Segall, is a Principal Investigator of this phase 3 program.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top